title: [Transcatheter aortic valve implantation].
abstract: As the French population is aging, a growing number of elderly patients with symptomatic severe aortic stenosis are going to require therapeutic management. Approximately 30 to 40 % of these patients do not undergo surgical treatment and a high proportion is considered to be at high risk for surgery. The transluminal aortic valve implantation technique has been increasingly used over the past few years, thus providing a solution to a major therapeutic issue in our industrialized countries. Thanks to major randomized studies such as the PARTNER US trial, this treatment has been approved for high-risk patients. Expertise and new devices are now opening the way to intermediate risk population.
authors.affiliation: Hôpital privé Jacques-Cartier, institut cardiovasculaire Paris Sud, 6, avenue du Noyer Lambert, 91300, Massy, France. Electronic address: t.hovasse@angio-icps.com.
authors.forename: T
authors.initials: T
authors.lastname: Hovasse
authors.affiliation: Hôpital privé Jacques-Cartier, institut cardiovasculaire Paris Sud, 6, avenue du Noyer Lambert, 91300, Massy, France.
authors.forename: T
authors.initials: T
authors.lastname: Lefevre
mesh_terms: D000368:Aged; D001021:Aortic Valve / Q000601:surgery*; D001024:Aortic Valve Stenosis / Q000601:surgery*; D006328:Cardiac Catheterization / Q000379:methods*; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000379:methods*; D006801:Humans; D011157:Population Dynamics; D011474:Prosthesis Design; D016032:Randomized Controlled Trials as Topic
keywords: Anneau aortique; Aortic annulus; Aortic stenosis; Cardiac CT; Hearteam; PARTNER trial; Rétrécissement aortique; Scanner cardiaque; TAVI; Valves percutanées; Étude PARTNER US